Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Post-Trial Drug Access
Drugs
Locations
Clinical Specialty
501-520 of 847 trials

Futibatinib Safety Study for Cancer Patients

We are collecting long-term safety information for patients who previously benefited from futibatinib treatment. This study helps ensure that continuing the medication remains safe for them.

Malignant Solid Tumors1-2 yearsEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Primary Hyperoxaluria: DCR-PHXC Injection Study

We are evaluating a new injection for patients with Primary Hyperoxaluria to see how it affects kidney function and overall safety. The study also looks at its impact on kidney stones and quality of life.

Primary Hyperoxaluria>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteEndocrinologyNephrology

Multiple Myeloma: SABLe Study with Selinexor

We are investigating a new treatment combination for patients with newly diagnosed multiple myeloma who cannot have a transplant. The study aims to evaluate how well the treatment works and its effects on quality of life.

Multiple Myeloma>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteHematologyOncology

Migraine Prevention in Kids: Rimegepant Study

We are testing a new medication, rimegepant, to see if it helps reduce migraine days in children and adolescents aged 6 to under 18. The study compares its effects to a placebo to understand its potential benefits.

Migraine≤3 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessStandard MedicinesPartially RemoteNeurologyPediatrics

Duchenne Muscular Dystrophy: Satralizumab Study

We are studying the effects of satralizumab in children and teens with Duchenne muscular dystrophy. This trial aims to see if it is safe and how it impacts bone health and metabolism.

Duchenne Muscular Dystrophy>2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesGastroenterologyNeurologyPediatrics

Plaque Psoriasis: TAK-279 Oral Medication

We are studying a new daily oral treatment for people with moderate-to-severe plaque psoriasis. The trial will help us understand its long-term safety and effectiveness.

Plaque Psoriasis>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementDermatology

Plaque Psoriasis: Zasocitinib vs. Deucravacitinib

We are studying whether a new oral medication, zasocitinib, is more effective than deucravacitinib for treating moderate-to-severe plaque psoriasis. The trial will also assess the safety and tolerability of both treatments.

Plaque Psoriasis6-12 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementDermatology

HER2-Positive Gastric Cancer: Rilvegostomig Treatment Study

We are comparing a new treatment combining rilvegostomig with other medications to standard therapies for patients with HER2-positive gastric cancer. The goal is to see if this new approach improves survival and reduces disease progression.

HER2-positive Gastric Cancer>2 yearsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Urinary Tract Infections: OM-89 Treatment Study

We are investigating whether OM-89 can help reduce antibiotic use in patients with a neurological bladder due to spinal cord injury. This study will compare its effects to a placebo over two years.

Recurrent Urinary Tract InfectionsNeurogenic Bladder1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessStandard MedicinesPartially RemoteInfectious DiseasesUrology

GTX-102 for Children with Angelman Syndrome

We are studying whether GTX-102 can improve cognitive function and other skills in children with deletion-type Angelman Syndrome. The trial also aims to evaluate the safety of this new treatment.

Angelman's Syndrome>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

Advanced Solid Tumors: Repotrectinib Study

We are testing a new treatment called repotrectinib for patients with advanced solid tumors that have specific genetic changes. The study aims to evaluate its safety and effectiveness in improving tumor response.

Advanced Solid Tumors3-6 monthsSafety phase (I)Efficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOncology

Crohn's Disease: SAR441566 Treatment Study

We are investigating how different doses of SAR441566 affect symptoms and health in adults with moderate to severe Crohn's disease. This study aims to find out if the medication can help improve patients' quality of life and overall condition.

Crohn's Disease1-2 yearsEfficacy phase (II)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal Medicine

Thyroid Eye Disease: Batoclimab Extension Study

We are studying the long-term effects of batoclimab in people with Thyroid Eye Disease who previously participated in earlier studies. The goal is to see if it continues to help reduce eye bulging and benefits those who didn't respond to earlier treatments.

Thyroid Eye Disease3-6 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOphthalmology

Systemic Juvenile Idiopathic Arthritis: Sarilumab Study

We are testing the medication sarilumab in children and adolescents with systemic juvenile idiopathic arthritis to find the best dose and understand its effects and safety.

Systemic Juvenile Idiopathic Arthritis (sJIA)3-6 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemotePediatricsRheumatology

Relapsing Multiple Sclerosis: Obexelimab Study

We are testing a new medication, Obexelimab, to see if it helps prevent new brain lesions in people with relapsing multiple sclerosis. The study will also assess the safety of this treatment compared to a placebo.

Relapsing-Remitting Multiple Sclerosis1-2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementInternal MedicineNeurology

INZ-701 for ENPP1 and ABCC6 Deficiency

We are studying the long-term safety of INZ-701 in patients with ENPP1 and ABCC6 deficiencies. This trial will help us understand how the drug works over time and its effects on certain blood markers.

Pseudoxanthoma ElasticumEctonucleotide Pyrophosphatase/Phosphodiesterase 1 DeficiencyGeneralized Arterial Calcification of InfancyEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteDermatologyInternal Medicine

Acute Myeloid Leukemia: Revumenib with Azacitidine and Venetoclax

We are studying whether adding revumenib to azacitidine and venetoclax helps adults with newly diagnosed NPM1-mutated AML who cannot receive intensive chemotherapy. The goal is to see if this combination improves survival and treatment response.

Acute Myeloid LeukemiaConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesOncology

Migraine Treatment: Rimegepant for Kids and Teens

We are studying the safety of rimegepant for treating migraines in children and adolescents aged 6 to under 18. This trial will help us understand how well the medication works and if there are any side effects.

Migraine1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteNeurology

Non-Transfusion-Dependent Thalassemia: Mitapivat Study

We are studying whether Mitapivat can improve anemia in people with non-transfusion-dependent alpha or beta thalassemia. This trial compares the medication to a placebo to evaluate its effects.

Non-Transfusion Dependent Thalassemia3-6 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteHematology

Acute Myeloid Leukemia: Ivosidenib, Azacitidine, and Venetoclax Study

We are investigating whether adding venetoclax to ivosidenib and azacitidine helps patients with newly diagnosed IDH1-mutated AML who cannot undergo intensive chemotherapy. The goal is to see if this combination improves survival and remission rates.

Acute Myeloid Leukemia>2 yearsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesOncology